LIVE

IMVT

Immunovant, Inc.

IMVT

NASDAQ·Healthcare·Biotechnology·Mkt cap $7.8B

$38.79

▲ +1.70%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$14.32 - $39.28

P/E

-14.42

Fwd P/E

-15.22

Beta

0.79

Div Yield

0.00%

Avg Vol

2.0M

Shares Out

203.5M

Mkt Cap

$7.8B

Price action

Price chart

Up 126.9% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Fully human monoclonal antibody technology with reduced immunogenicity risk
  • Selective FcRn inhibition mechanism targeting root cause of autoimmune pathology
  • Multi-indication development strategy across large patient populations with high unmet medical need
  • Backing from Roivant Sciences providing capital and operational support
▼

Bear Case

1 risk

  • Low volatility (beta 0.8).

Growth

Revenue decline expected

Clinical trial progression in myasthenia gravis and thyroid eye disease with potential for accelerated approval pathways

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+55.7% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 10, 2026

“
Q2 26 RECAP

MAY 20, 2026

Reported EPS of -$0.73 vs -$0.60 consensus (-21.7% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-21.7%

Next: Aug 10, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q4 24

Q1 24

Q2 24

Q3 24

Q4 25

Q1 25

Q2 25

Q3 25

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

7 analysts · 71% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

5

71%

Hold

2

29%

Sell

0%

Median Price Target

$40.00

▲ +3.1% vs $38.79

Low $40.00
Median $40.00
High $40.00

Latest: Citi · Jun 30, 2026

1 analyst covering

View full analyst page →

vs Industry

How IMVT stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.